drugset / Trial / NCT02231450
Pharmacokinetics Properties of Single Oral Dosing of Lu AE58054 in Subjects With Hepatic Impairment (Mild and Moderate) and in Healthy Subjects
Non-randomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study is to assess the impact of mild to moderate hepatic impairment on the pharmacokinetics of Lu AE58054 following a single oral dose of Lu AE58054
Timeline
- Start
- 2014-07
- Primary completion
- 2015-03
- Completion
- —
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Idalopirdine | Small molecule | 60 mg | Oral |
Indications
No indication recorded.